Loading…
← CockpitCompetitor Analysis › 301263.SZ Guangdong Taienkang Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Guangdong Taienkang Pharmaceutical Co., Ltd. Class A301263.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Guangdong-based pharmaceutical manufacturer selling generic and specialty drugs in China.

Momentum neutral 54
Mkt cap
$1.30B
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$11.2M
20-day average traded
Fwd P/E
60.7×
forward earnings
ROIC−WACC
-6.6 pp
WACC 8.3%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥17.11
1D-3.6%
1W-12.4%
1M-6.8%
3M-16.9%
6M-23.7%
YTD-29.2%
1Y-32.9%
ATR %4.8%
52w lowhigh42.5% off high

What Guangdong Taienkang Pharmaceutical does

Guangdong-based pharmaceutical manufacturer selling generic and specialty drugs in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics

Moat: none

Headquarters: Guangdong, China · Employees: 1,154

Guangdong Taienkang Pharmaceutical at a glance

Size Guangdong Taienkang Pharmaceutical (301263.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.30B, the 1733rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.11 on 18 Nov 2026.

Performance Over six months the shares fell 23.7%, against -15.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 1.8% over the last twelve months (peer median +9.2%); the operating margin is -2.1% (peer median 2.8%).

Valuation It trades at 60.7× forward earnings against a peer median of 18.2× (3rd most expensive of 11).

Capital Return on invested capital runs 6.6 points below its cost of capital (8.3% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 85301263.SZ 78
Six months, rebased to 100: Guangdong Taienkang Pharmaceutical against the median of its 20 peers (local-currency closes).

Guangdong Taienkang Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥682MCN¥670MCN¥711MCN¥755MCN¥779M
Revenue growth—-6%-6%-3%—
Gross profitCN¥407MCN¥325MCN¥371MCN¥430MCN¥434M
EBITDAn/aCN¥67.2MCN¥159MCN¥219MCN¥225M
Net incomeCN¥28.7MCN¥28.6MCN¥108MCN¥160MCN¥175M
Free cash flow-CN¥11.0M-CN¥119MCN¥25.3M-CN¥97.9MCN¥68.3M
Capital expenditureCN¥140MCN¥108MCN¥68.6MCN¥200MCN¥89.9M
Total debtCN¥617MCN¥366MCN¥247MCN¥176MCN¥23.2M

Quarterly statements and history in the cockpit →

Guangdong Taienkang Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%LBRXOCULINVAMNKD002332688293AMPH068760002099300204GHRSNANO226950GPCRAVLN300026301263.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Guangdong Taienkang Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×200×400×INVAMNKD002332688293300204300026301263.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guangdong Taienkang Pharmaceutical is the large dot.

Guangdong Taienkang Pharmaceutical competitors and peer comparison

How Guangdong Taienkang Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guangdong Taienkang Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure301263.SZPeer medianRank in peer set
1-month return-6.8%-4.3%6th lowest of 20
6-month return-23.7%-15.6%7th lowest of 20
Distance from 52-week high-42.5%-35.8%7th lowest of 20
Revenue growth (TTM)+1.8%+9.2%6th lowest of 16
Operating margin-2.1%2.8%6th lowest of 16
Forward P/E60.7×18.2×3rd most expensive of 11
ROIC minus cost of capital-6.6 pp-3.3 pp6th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%n/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%n/an/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%

Questions

Which companies are Guangdong Taienkang Pharmaceutical's closest peers?
The cockpit's peer set: LB Pharmaceuticals (LBRX), Ocular Therapeutix (OCUL), Innoviva (INVA), MannKind (MNKD), Zhejiang Xianju Pharmaceutical (002332.SZ), Windward Bio (WWB), Shanghai OPM Biosciences (688293.SS), Amphastar Pharmaceuticals (AMPH).
Is Guangdong Taienkang Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 60.7× against a peer median of 18.2×, 3rd most expensive of 11 in its peer set.
How has Guangdong Taienkang Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -23.7% against -15.6% for the median peer; over one year -32.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.